Genetic Variation in OAS1 is a Risk Factor for Initial Infection with West Nile Virus in Man

Overview

Journal PLoS Pathog

Specialty Microbiology

Date 2009 Feb 28

PMID 19247438

Citations 130

Authors

Jean K Lim

Andrea Lisco

David H McDermott

Linda Huynh

Jerrold M Ward

Bernard Johnson

Hope Johnson

John Pape

Gregory A Foster

David Krysztof

Dean Follmann

Susan L Stramer

Leonid B Margolis

Philip M Murphy

Affiliations

Soon will be listed here.

Abstract

West Nile virus (WNV) is a re-emerging pathogen that can cause fatal encephalitis. In mice, susceptibility to WNV has been reported to result from a single point mutation in oas1b, which encodes 2'-5' oligoadenylate synthetase 1b, a member of the type I interferon-regulated OAS gene family involved in viral RNA degradation. In man, the human ortholog of oas1b appears to be OAS1. The 'A' allele at SNP rs10774671 of OAS1 has previously been shown to alter splicing of OAS1 and to be associated with reduced OAS activity in PBMCs. Here we show that the frequency of this hypofunctional allele is increased in both symptomatic and asymptomatic WNV seroconverters (Caucasians from five US centers; total n = 501; OR = 1.6 [95% CI 1.2-2.0], P = 0.0002 in a recessive genetic model). We then directly tested the effect of this SNP on viral replication in a novel ex vivo model of WNV infection in primary human lymphoid tissue. Virus accumulation varied markedly among donors, and was highest for individuals homozygous for the 'A' allele (P<0.0001). Together, these data identify OAS1 SNP rs10774671 as a host genetic risk factor for initial infection with WNV in humans.

Citing Articles

Comprehensive mapping of genetic variation at Epromoters reveals pleiotropic association with multiple disease traits.

Wan J, van Ouwerkerk A, Mouren J, Heredia C, Pradel L, Ballester B Nucleic Acids Res. 2024; 53(4).

PMID: 39727170 PMC: 11879118. DOI: 10.1093/nar/gkae1270.

The canonical antiviral protein oligoadenylate synthetase 1 elicits antibacterial functions by enhancing IRF1 translation.

Harioudh M, Perez J, So L, Maheshwari M, Ebert T, Hornung V Immunity. 2024; 57(8):1812-1827.e7.

PMID: 38955184 PMC: 11324410. DOI: 10.1016/j.immuni.2024.06.003.

Transcriptome analysis of cynomolgus macaques throughout their lifespan reveals age-related immune patterns.

Cho H, Choe S, Lee J, Park H, Ko M, Lee Y NPJ Aging. 2024; 10(1):30.

PMID: 38902280 PMC: 11189941. DOI: 10.1038/s41514-024-00158-0.

Prevalence of the protective OAS1 rs10774671-G allele against severe COVID-19 in Moroccans: implications for a North African Neanderthal connection.

Yousfi F, Haroun A, Nebhani C, Belayachi J, Askander O, El Fahime E Arch Virol. 2024; 169(5):109.

PMID: 38658463 PMC: 11043147. DOI: 10.1007/s00705-024-06038-y.

Gastrointestinal microbiota and metabolites possibly contribute to distinct pathogenicity of SARS-CoV-2 proto or its variants in rhesus monkeys.

Chen H, Wang J, Ding K, Xu J, Yang Y, Tang C Gut Microbes. 2024; 16(1):2334970.

PMID: 38563680 PMC: 10989708. DOI: 10.1080/19490976.2024.2334970.

References

Hubalek Z, Halouzka J . West Nile fever--a reemerging mosquito-borne viral disease in Europe. Emerg Infect Dis. 1999; 5(5):643-50. PMC: 2627720. DOI: 10.3201/eid0505.990505. View

Perelygin A, Scherbik S, Zhulin I, Stockman B, Li Y, Brinton M . Positional cloning of the murine flavivirus resistance gene. Proc Natl Acad Sci U S A. 2002; 99(14):9322-7. PMC: 123139. DOI: 10.1073/pnas.142287799. View

Lewis M, Amsden J . Successful treatment of West Nile virus infection after approximately 3 weeks into the disease course. Pharmacotherapy. 2007; 27(3):455-8. DOI: 10.1592/phco.27.3.455. View

Lanciotti R, Roehrig J, Deubel V, Smith J, Parker M, Steele K . Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science. 1999; 286(5448):2333-7. DOI: 10.1126/science.286.5448.2333. View

Zimmerman P, Buckler-White A, Alkhatib G, Spalding T, Kubofcik J, Combadiere C . Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol Med. 1997; 3(1):23-36. PMC: 2230106. View

Hayes E, Gubler D . West Nile virus: epidemiology and clinical features of an emerging epidemic in the United States. Annu Rev Med. 2006; 57:181-94. DOI: 10.1146/annurev.med.57.121304.131418. View

Chan-Tack K, Forrest G . Failure of interferon alpha-2b in a patient with West Nile virus meningoencephalitis and acute flaccid paralysis. Scand J Infect Dis. 2005; 37(11-12):944-6. DOI: 10.1080/00365540500262690. View

He J, Feng D, de Vlas S, Wang H, Fontanet A, Zhang P . Association of SARS susceptibility with single nucleic acid polymorphisms of OAS1 and MxA genes: a case-control study. BMC Infect Dis. 2006; 6:106. PMC: 1550407. DOI: 10.1186/1471-2334-6-106. View

Asnis D, Conetta R, Teixeira A, Waldman G, Sampson B . The West Nile Virus outbreak of 1999 in New York: the Flushing Hospital experience. Clin Infect Dis. 2000; 30(3):413-8. DOI: 10.1086/313737. View

10.

Hovanessian A, Justesen J . The human 2'-5'oligoadenylate synthetase family: unique interferon-inducible enzymes catalyzing 2'-5' instead of 3'-5' phosphodiester bond formation. Biochimie. 2007; 89(6-7):779-88. DOI: 10.1016/j.biochi.2007.02.003. View

11.

Bourne N, Scholle F, Silva M, Rossi S, Dewsbury N, Judy B . Early production of type I interferon during West Nile virus infection: role for lymphoid tissues in IRF3-independent interferon production. J Virol. 2007; 81(17):9100-8. PMC: 1951458. DOI: 10.1128/JVI.00316-07. View

12.

Rios M, Zhang M, Grinev A, Srinivasan K, Daniel S, Wood O . Monocytes-macrophages are a potential target in human infection with West Nile virus through blood transfusion. Transfusion. 2006; 46(4):659-67. DOI: 10.1111/j.1537-2995.2006.00769.x. View

13.

Mostashari F, Bunning M, Kitsutani P, Singer D, Nash D, Cooper M . Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey. Lancet. 2001; 358(9278):261-4. DOI: 10.1016/S0140-6736(01)05480-0. View

14.

Sangster M, Heliams D, MacKenzie J, Shellam G . Genetic studies of flavivirus resistance in inbred strains derived from wild mice: evidence for a new resistance allele at the flavivirus resistance locus (Flv). J Virol. 1993; 67(1):340-7. PMC: 237368. DOI: 10.1128/JVI.67.1.340-347.1993. View

15.

Glushakova S, Baibakov B, Margolis L, Zimmerberg J . Infection of human tonsil histocultures: a model for HIV pathogenesis. Nat Med. 1995; 1(12):1320-2. DOI: 10.1038/nm1295-1320. View

16.

Field L, Bonnevie-Nielsen V, Pociot F, Lu S, Nielsen T, Beck-Nielsen H . OAS1 splice site polymorphism controlling antiviral enzyme activity influences susceptibility to type 1 diabetes. Diabetes. 2005; 54(5):1588-91. DOI: 10.2337/diabetes.54.5.1588. View

17.

Mashimo T, Lucas M, Simon-Chazottes D, Frenkiel M, Montagutelli X, Ceccaldi P . A nonsense mutation in the gene encoding 2'-5'-oligoadenylate synthetase/L1 isoform is associated with West Nile virus susceptibility in laboratory mice. Proc Natl Acad Sci U S A. 2002; 99(17):11311-6. PMC: 123253. DOI: 10.1073/pnas.172195399. View

18.

Yakub I, Lillibridge K, Moran A, Gonzalez O, Belmont J, Gibbs R . Single nucleotide polymorphisms in genes for 2'-5'-oligoadenylate synthetase and RNase L inpatients hospitalized with West Nile virus infection. J Infect Dis. 2005; 192(10):1741-8. DOI: 10.1086/497340. View

19.

Rogozin I, Aravind L, Koonin E . Differential action of natural selection on the N and C-terminal domains of 2'-5' oligoadenylate synthetases and the potential nuclease function of the C-terminal domain. J Mol Biol. 2003; 326(5):1449-61. DOI: 10.1016/s0022-2836(03)00055-x. View

20.

Smyth D, Cooper J, Lowe C, Nutland S, Walker N, Clayton D . No evidence for association of OAS1 with type 1 diabetes in unaffected siblings or type 1 diabetic cases. Diabetes. 2006; 55(5):1525-8. DOI: 10.2337/db05-1452. View